Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients

Authors

Ema Mosleh, Washington University School of Medicine in St. Louis
Stacy Snyder, Washington University School of Medicine in St. Louis
Ningying Wu, Washington University School of Medicine in St. Louis
Daniel N Willis, Washington University School of Medicine in St. Louis
Rema Malone, St. Louis Children's Hospital
Robert J Hayashi, Washington University School of Medicine in St. Louis

Journal

Frontiers in Oncology

Publication Date

1-1-2023

Volume

13

First Page

1280587

Document Type

Open Access Publication

DOI

10.3389/fonc.2023.1280587

Rights and Permissions

Mosleh E, Snyder S, Wu N, Willis DN, Malone R and Hayashi RJ (2023) Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients. Front. Oncol. 13:1280587. doi: 10.3389/fonc.2023.1280587 © 2023 Mosleh, Snyder, Wu, Willis, Malone and Hayashi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Recommended Citation

Mosleh, Ema; Snyder, Stacy; Wu, Ningying; Willis, Daniel N; Malone, Rema; and Hayashi, Robert J, "Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients." Frontiers in Oncology. 13, 1280587 (2023).
https://digitalcommons.wustl.edu/oa_4/3565

Department

ICTS (Institute of Clinical and Translational Sciences)